Receptor tyrosine kinase inhibitors in cancer

Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, Sahar Palizdar, Roya Khorram, Reza Vafadar, Halimeh Mobarak, Amirhossein Ahmadi, Michael R Hamblin, Amir Reza Aref

Article2021

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

Chloe Pek Sang Tang, Professor Gregory Lip, Terry McCormack, Alexander R. Lyon, Peter Hillmen, Sunil Iyengar, Nicolás Martínez‐Calle, Nilima Parry‐Jones, Piers Patten, Anna Schuh, Renata Walewska

Article2017

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

Nicole Glodde, Tobias Bald, Debby van den Boorn-Konijnenberg, Kyohei Nakamura, Jake S. O’Donnell, Sabrina Szczepanski, Maria Brandes, Sarah Eickhoff, Indrajit Das, Naveen Shridhar, Daniel Hinze, Meri Rogava, Tetje C. van der Sluis, Janne Ruotsalainen, Evelyn Gaffal, Jennifer Landsberg, Kerstin U. Ludwig, Christoph Wilhelm, Monika Riek‐Burchardt, Andreas J. Müller, Christoffer Gebhardt, Richard A Scolyer, Georgina V. Long,

Article2022

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

Adriana Petrazzuolo, Maria Chiara Maiuri, Laurence Zitvogel, Guido Guido Kroemer, Oliver Kepp

Article2004

Bruton’s tyrosine kinase (Btk)—the critical tyrosine kinase in LPS signalling?

Caroline A. Jefferies, Luke O'neill

Immunology Letters

Viktor Janzen,

Michele W.L. Teng,

Wolfgang Kastenmüller,

Massimiliano Mazzone,

Mark J. Smyth,

Thomas Tüting,

Michael Hölzel